Interventional Cardiology Market By Product Type (Coronary Stents, Catheters, Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons, Percutaneous Transluminal Coronary Angioplasty (PTCA) Guide Wires, Endovascular Aneurysm Repair Stent Grafts, Inferior Vena Cava (IVC) Filters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices And Others), By End Users (Hospitals, Cardiac Catheterization Laboratories, Ambulatory Surgical Centers, Others), And Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Interventional Cardiology Market size was valued at USD 19,274.6 million in 2022 and is expected to grow at a 9.0% CAGR from 2023 to 2029. Interventional cardiology is a subspeciality in the cardiology that uses specialized catheter-based techniques to diagnose and treat various heart disease like congenital heart disease, coronary artery disease, vascular disease and others. The interventional cardiology uses various imaging and diagnostic tools to diagnose cardiovascular functions such as blood flow, blood pressure in major arteries in our body. The evolution of interventional cardiology technique has eliminated the traditional open-heart surgeries. The Rapid increase in geriatric population, increasing awareness of cardiovascular drugs disease and the increase in consciousness of people to monitor cardiac health, rapid increase in chronic diseases like diabetes, cardiac makers disease among the population is expected to drive the growth of interventional cardiology market in the forecasted years. Furthermore, increasing incidence of cardiovascular disease along with the growing healthcare expenditure in medical device is expected to push the market growth in the forecasted years. In addition, the rise in tobacco consumption and the growing incidence of obesity is also expected to fuel the growth of interventional cardiology market. Several government and non-government organizations including educational institutes and key market payers, have conducted public awareness campaigns to raise the awareness regarding cardiac disease and its treatments. The advancement of technology and procedures in healthcare facility like innovative cardiovascular devices and regulatory approvals are expected to fuel the growth of interventional cardiology market in the forecasted years. However, the huge cost of interventional cardiac devices and the availability of alternative cardiac disease treatments are expected to hinder the growth of interventional cardiology market in the forecasted years. Geographically, North America region held the major market share in 2022 and is expected to dominate the global interventional cardiology market in the forecasted years.

Interventional Cardiology Market Key Developments:
In July 2021, Abbott launched its product XIENCE family of stents, which got USFDA’s approval for one month DAPT labeling for patients with high bleeding risk in US.

Interventional Cardiology Market Summary

Study Period

2023 – 29

Base Year

2022

CAGR

9%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Interventional Cardiology Market Dynamics

Interventional cardiology market is expected to grow due to the increasing prevalence cardiac diseases, the increase in number of geriatric patients across the globe. The increase in tobacco consumption and number of obesity population is expected to increase the demand and fuel the growth of interventional cardiology market. The increase in investments in research and development by market players and the launch of advanced products for better enhanced treatment and to launch new product portfolios are expected to boost the growth of interventional cardiology market. However, strict regulations for the manufacture of interventional cardiology devices and availability of effective first line treatment are expected to hinder the growth of interventional cardiology market in the forecasted years.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Interventional Cardiology Market Segmentation

By Product Type
  • Coronary Stents
  • Catheters
  • Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons
  • Percutaneous Transluminal Coronary Angioplasty (PTCA) Guide Wires
  • Endovascular Aneurysm Repair Stent Grafts
  • Inferior Vena Cava (IVC) Filters
  • Plaque Modification Devices
  • Hemodynamic Flow Alteration Devices
  • Others
By End Users
  • Hospitals
  • Cardiac Catheterization Laboratories
  • Ambulatory Surgical Centers
  • Others
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA
LOCATION

Geography

Frequently Asked Questions

Interventional Cardiology market was valued at USD 19,274.6 million in 2022 and is expected to grow at a 9.0% CAGR from 2023 to 2029

Increase in prevalence of cardiac disease and increased consumption of tobacco are expected to provide opportunity to the key market players in interventional cardiology market.

The leading players in the global Interventional Cardiology market are ABIOMED Inc., ACIST Medical Systems, B. Braun Melsungen AG, Biotronik SE & Co., Boston Scientific Corporation, Cardinal Health, Edwards Lifesciences Corporation, Johnson & Johnson Services, Inc., Medtronic, Merit Medical Systems, Koninklijke Philips N.V., Abbott, Terumo Corporation, Rontis Corporation Inc., Biosensors International Group Ltd.

Availability of alternative treatment and high cost of interventional cardiac devices are expected to restrain the growth of interventional cardiology market.

  • ABIOMED Inc.
  • ACIST Medical Systems
  • B. Braun Melsungen AG
  • Biotronik SE & Co.
  • Boston Scientific Corporation
  • Cardinal Health
  • Edwards Lifesciences Corporation
  • Johnson & Johnson Services Inc.
  • Medtronic
  • Merit Medical Systems
  • Koninklijke Philips N.V.
  • Abbott
  • Terumo Corporation
  • Rontis Corporation Inc.
  • Biosensors International Group Ltd.